{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:44:20Z","timestamp":1789641860682,"version":"4.0.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0253-7613.161249","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T05:15:05Z","timestamp":1437455705000},"page":"354","source":"Crossref","is-referenced-by-count":112,"title":["Imiquimod - Its role in the treatment of cutaneous malignancies"],"prefix":"10.4103","volume":"47","author":[{"given":"AdityaKumar","family":"Bubna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.161249-1","first-page":"S6","volume-title":"Immunomodulatory and pharmacologic properties of imiquimod","author":"Sauder","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0253-7613.161249-2","first-page":"4","volume-title":"Imiquimod 5 percent cream and the treatment of cutaneous malignancy","author":"Navi","year":"2004","journal-title":"Dermatol Online J"},{"key":"key-10.4103\/0253-7613.161249-3","first-page":"XV","volume-title":"Imiquimod: Unexpected killer","author":"Leverkus","year":"2004","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0253-7613.161249-4","first-page":"1002","volume-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","author":"Beutner","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0253-7613.161249-5","first-page":"466","volume-title":"Imiquimod","author":"Jobanputra","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0253-7613.161249-6","first-page":"227","volume-title":"Zyclara (imiquimod) cream, 3.75%","author":"Gupta","year":"2010","journal-title":"Skinmed"},{"key":"key-10.4103\/0253-7613.161249-7","first-page":"11","volume-title":"Actinic keratosis: Rationale and management","author":"Dodds","year":"2014","journal-title":"Dermatol Ther (Heidelb)"},{"key":"key-10.4103\/0253-7613.161249-8","first-page":"25","volume-title":"Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients","author":"Ulrich","year":"2007","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0253-7613.161249-9","first-page":"571","volume-title":"Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial","author":"Salasche","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0253-7613.161249-10","first-page":"36","volume-title":"An investigator-initiated study to assess the safety and efficacy of imiquimod 3.75% cream when used after cryotherapy in the treatment of hypertrophic actinic keratoses on dorsal hands and forearms","author":"Goldenberg","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"key-10.4103\/0253-7613.161249-11","first-page":"35","volume-title":"Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream","author":"Shaffelburg","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"key-10.4103\/0253-7613.161249-12","first-page":"5574","volume-title":"Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor\/protein kinase A-mediated GLI phosphorylation","author":"Wolff","year":"2013","journal-title":"Oncogene"},{"key":"key-10.4103\/0253-7613.161249-13","first-page":"567","volume-title":"An old friend with new skills: Imiquimod as novel inhibitor of Hedgehog signaling in basal cell carcinoma","author":"Gruber","year":"2014","journal-title":"Oncoscience"},{"key":"key-10.4103\/0253-7613.161249-14","first-page":"1589","volume-title":"Interaction between differentiating cell- and niche-derived signals in hematopoietic progenitor maintenance","author":"Mondal","year":"2011","journal-title":"Cell"},{"key":"key-10.4103\/0253-7613.161249-15","first-page":"733","volume-title":"Overall treatment success after treatment of primary superficial basal cell carcinoma: A systematic review and meta-analysis of randomized and nonrandomized trials","author":"Roozeboom","year":"2012","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0253-7613.161249-16","first-page":"353","volume-title":"Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: A case series and review","author":"Lacarrubba","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/0253-7613.161249-17","doi-asserted-by":"crossref","unstructured":"Yang JQ, Chen XY, Engle MY, Wang JY. Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream. Dermatol Ther 2015. [Last accessed on 2015 Apr 25].","DOI":"10.1111\/dth.12217"},{"key":"key-10.4103\/0253-7613.161249-18","first-page":"19","volume-title":"The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin\u2032s syndrome","author":"Micali","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/0253-7613.161249-19","first-page":"197","volume-title":"Basal cell carcinoma: An evidence-based treatment update","author":"Clark","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/0253-7613.161249-20","first-page":"96","volume-title":"Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): A multicentre, non-inferiority, randomised controlled trial","author":"Bath-Hextall","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0253-7613.161249-21","first-page":"1361","volume-title":"Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT 3 VIN): A multicentre, open-label, randomised, phase 2 trial","author":"Tristram","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0253-7613.161249-22","first-page":"66","volume-title":"Efficacy of 5% imiquimod cream on vulvar intraepithelial neoplasia in Korea: Pilot study","author":"Kim","year":"2015","journal-title":"Ann Dermatol"},{"key":"key-10.4103\/0253-7613.161249-23","first-page":"87","volume-title":"Advances in the use of topical imiquimod to treat dermatologic disorders","author":"Lacarrubba","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"key-10.4103\/0253-7613.161249-24","first-page":"936","volume-title":"Imiquimod 5% cream versus cold knife excision for treatment of VIN 2\/3: A five-year follow-up","author":"Frega","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key-10.4103\/0253-7613.161249-25","first-page":"2331","volume-title":"A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod","author":"Fox","year":"2010","journal-title":"AIDS"},{"key":"key-10.4103\/0253-7613.161249-26","first-page":"e95337","volume-title":"Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20","author":"Sohn","year":"2014","journal-title":"PLoS One"},{"key":"key-10.4103\/0253-7613.161249-27","first-page":"482","volume-title":"Treatment options in melanoma in situ: Topical and radiation therapy, excision and Mohs surgery","author":"Erickson","year":"2010","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0253-7613.161249-28","first-page":"1191","volume-title":"Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: A study of 43 patients","author":"Ly","year":"2011","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0253-7613.161249-29","first-page":"994","volume-title":"Imiquimod and lentigo maligna: A search for prognostic features in a clinicopathological study with long-term follow-up","author":"Powell","year":"2009","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0253-7613.161249-30","first-page":"1661","volume-title":"How imiquimod licenses plasmacytoid dendritic cells to kill tumors","author":"Holcmann","year":"2012","journal-title":"Oncoimmunology"},{"key":"key-10.4103\/0253-7613.161249-31","first-page":"2551","volume-title":"Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization","author":"Aspord","year":"2014","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0253-7613.161249-32","first-page":"61","volume-title":"Emerging treatment options for early mycosis fungoides","author":"Fernandez-Guarino","year":"2013","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"key-10.4103\/0253-7613.161249-33","first-page":"644","volume-title":"Treatment of extramammary Paget disease of the vulva with imiquimod: A retrospective, multicenter study by the German Colposcopy Network","author":"Luyten","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0253-7613.161249-34","first-page":"479","volume-title":"Imiquimod therapy for extramammary Paget\u2032s disease of the vulva: A viable non-surgical alternative","author":"Sanderson","year":"2013","journal-title":"J Obstet Gynaecol"},{"key":"key-10.4103\/0253-7613.161249-35","first-page":"82","volume-title":"Sequential use with imiquimod and surgery in extramammary Paget\u2032s disease","author":"Toledo","year":"2012","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/0253-7613.161249-36","first-page":"150","volume-title":"Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma","author":"Hu","year":"2015","journal-title":"Dermatology"},{"key":"key-10.4103\/0253-7613.161249-37","first-page":"141","volume-title":"Merkel cell carcinoma: Recent insights and new treatment options","author":"Schrama","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"key-10.4103\/0253-7613.161249-38","first-page":"508","volume-title":"Treatment of Merkel cell carcinoma with radiotherapy and imiquimod (Aldara): A case report","author":"Balducci","year":"2010","journal-title":"Tumori"},{"key":"key-10.4103\/0253-7613.161249-39","first-page":"52","volume-title":"Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma","author":"G\u00fcnd\u00fcz","year":"2012","journal-title":"J Dermatol Case Rep"},{"key":"key-10.4103\/0253-7613.161249-40","first-page":"147","volume-title":"Treatment of classic Kaposi\u2032s sarcoma with topical imiquimod","author":"Goiriz","year":"2009","journal-title":"Dermatol Surg"},{"key":"key-10.4103\/0253-7613.161249-41","first-page":"417","volume-title":"Imiquimod for the treatment of classical Kaposi\u2032s sarcoma","author":"Bernardini","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/0253-7613.161249-42","first-page":"6571","volume-title":"Breast cancer treatment with imiquimod: Applying an old lotion to a new disease","author":"Kohrt","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0253-7613.161249-43","first-page":"6748","volume-title":"Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer","author":"Adams","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0253-7613.161249-44","first-page":"6668","volume-title":"Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer","author":"Dewan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0253-7613.161249-45","first-page":"e22","volume-title":"Imiquimod in the treatment of breast cancer skin metastasis","author":"Henriques","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:37Z","timestamp":1786649857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.161249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"alternative-id":["161249"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.161249","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}